Israel Englander Tempest Therapeutics, Inc. Call Options Transaction History
Millennium Management LLC
- $175 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TPST
# of Institutions
26Shares Held
1.99MCall Options Held
42.8KPut Options Held
72.9K-
Black Rock Inc. New York, NY550KShares$4.19 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA433KShares$3.3 Million0.0% of portfolio
-
Ubs Group Ag324KShares$2.47 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA298KShares$2.27 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA115KShares$872,9390.0% of portfolio
About Tempest Therapeutics, Inc.
- Ticker TPST
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,418,900
- Market Cap $79.4M
- Description
- Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxiso...